{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:58:39Z","timestamp":1746187119958},"reference-count":33,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2022]]},"DOI":"10.3960\/jslrt.22026","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T22:11:00Z","timestamp":1672179060000},"page":"202-207","source":"Crossref","is-referenced-by-count":2,"title":["A multicenter, phase II study of full-dose THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, aggressive non-Hodgkin lymphoma"],"prefix":"10.3960","volume":"62","author":[{"given":"Ken","family":"Ohmachi","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michinori","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan,"},{"name":"Department of Hematology, Aichi Sannomaru Clinic, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitoyo","family":"Kagami","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Hirose","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Ohnishi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hamamatsu University School of Medicine, Hamamatsu, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomitsu","family":"Hotta","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","unstructured":"1 https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/cancer\/25_ml.html (last access: 17-June-2022)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Muto R, Miyoshi H, Sato K <i>et al.<\/i> Epidemiology and secular trends of malignant lymphoma in Japan: analysis of 9426 cases according to the World Health Organization classification. Cancer Med. 2018; 7: 5843-5858.","DOI":"10.1002\/cam4.1805"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Fisher RI, Gaynor ER, Dahlberg S <i>et al.<\/i> Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993; 328: 1002-1006.","DOI":"10.1056\/NEJM199304083281404"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Dixon DO, Neilan B, Jones SE <i>et al.<\/i> Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol. 1986; 4: 295-305.","DOI":"10.1200\/JCO.1986.4.3.295"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Meyer RM, Browman GP, Samosh ML <i>et al.<\/i> Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin\u2019s lymphoma. J Clin Oncol. 1995; 13: 2386-2393.","DOI":"10.1200\/JCO.1995.13.9.2386"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Sonneveld P, de Ridder M, van der Lelie H <i>et al.<\/i> Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin\u2019s lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol. 1995; 13: 2530-2539.","DOI":"10.1200\/JCO.1995.13.10.2530"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Umezawa H, Takahashi Y, Kinoshita M <i>et al.<\/i> Tetrahydropyranyl derivatives of daunomycin and adriamycin. J Antibiot (Tokyo). 1979; 32: 1082-1084.","DOI":"10.7164\/antibiotics.32.1082"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Matsushita Y, Kumagai H, Yoshimoto A <i>et al.<\/i> Antitumor activities of (2&quot;R)-4\u2032-O-tetrahydropyranyl-adriamycin (THP) and its combination with other antitumor agents on murine tumors. J Antibiot (Tokyo). 1985; 38: 1408-1419.","DOI":"10.7164\/antibiotics.38.1408"},{"key":"9","unstructured":"9 Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. 4\u2032-O-tetrahydropyranyladriamycin as a potential new antitumor agent. Cancer Res. 1982; 42: 1462-1467."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Dantchev D, Paintrand M, Hayat M, Bourut C, Math\u00e9 G. Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy. J Antibiot (Tokyo). 1979; 32: 1085-1086.","DOI":"10.7164\/antibiotics.32.1085"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Drings P, G\u00fcnther IU, Gatzemeier U <i>et al.<\/i> Pirarubicin in advanced non-small cell lung cancer. A trial of the Phase I\/II Study Group of the Association for Medical Oncology of the German Cancer Society. Onkologie. 1990; 13: 180-184.","DOI":"10.1159\/000216754"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Sridhar KS, Hussein AM, Benedetto P <i>et al.<\/i> Phase II trial of 4\u2032-O-tetrahydropyranyladriamycin (pirarubicin) in head and neck carcinoma. Cancer. 1992; 70: 1591-1597.","DOI":"10.1002\/1097-0142(19920915)70:6<1591::AID-CNCR2820700624>3.0.CO;2-6"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 The Non-Hodgkin\u2019s Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin\u2019s lymphomas: summary and description of a working formulation for clinical usage. Cancer. 1982; 49: 2112-2135.","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2"},{"key":"14","unstructured":"14 Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on hodgkin\u2019s disease staging classification. Cancer Res. 1971; 31: 1860-1861."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Tobinai K, Kohno A, Shimada Y <i>et al.<\/i> Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol. 1993; 23: 250-257.","DOI":"10.1093\/oxfordjournals.jjco.a039642"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981; 47: 207-214.","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013; 48: 452-458.","DOI":"10.1038\/bmt.2012.244"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Shipp MA. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993; 329: 987-994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981; 47: 207-214.","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Tirelli U, Errante D, Van Glabbeke M <i>et al.<\/i> CHOP is the standard regimen in patients &gt; or = 70 years of age with intermediate-grade and high-grade non-Hodgkin\u2019s lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol. 1998; 16: 27-34.","DOI":"10.1200\/JCO.1998.16.1.27"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Limat S, Demesmay K, Voillat L <i>et al.<\/i> Early cardiotoxicity of the CHOP regimen in aggressivenon-Hodgkin\u2019s lymphoma. Ann Oncol. 2003; 14: 277-281.","DOI":"10.1093\/annonc\/mdg070"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Niitsu N, Iijima K. Full-dose CHOP chemotherapy combined with granulocyte colony-stimulating factor for aggressive non-Hodgkin\u2019s lymphoma in elderly patients: a prospective study. Ann Hematol. 2001; 80: 602-606.","DOI":"10.1007\/s002770100358"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Kagami Y, Itoh K, Tobinai K <i>et al.<\/i> Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low-intermediate risk, aggressive non-Hodgkin\u2019s lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG9508. Int J Hematol. 2012; 96: 74-83.","DOI":"10.1007\/s12185-012-1101-2"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Ohmachi K, Tobinai K, Kobayashi Y <i>et al.<\/i> Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin\u2019s lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809. Ann Oncol. 2011; 22: 1382-1391.","DOI":"10.1093\/annonc\/mdq619"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Mori M, Kitamura K, Masuda M <i>et al.<\/i> Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin\u2019s lymphoma. Int J Hematol. 2005; 81: 246-254.","DOI":"10.1532\/IJH97.03147"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Tsurumi H, Hara T, Goto N <i>et al.<\/i> A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol. 2007; 25: 107-114.","DOI":"10.1002\/hon.815"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003; 97: 2869-2879.","DOI":"10.1002\/cncr.11407"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Herait P, Poutignat N, Marty M, Bugat R. Early assessment of a new anticancer drug analogue -- are the historical comparisons obsolete? The French experience with pirarubicin. Eur J Cancer. 1992; 28: 1670-1676.","DOI":"10.1016\/0959-8049(92)90066-B"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Zhai L, Guo C, Cao Y <i>et al.<\/i> Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin\u2019s lymphoma: single center, 15-year experience. Int J Hematol. 2010; 91: 78-86.","DOI":"10.1007\/s12185-009-0461-8"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Legha SS, Benjamin RS, Mackay B <i>et al.<\/i> Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982; 96: 133-139.","DOI":"10.7326\/0003-4819-96-2-133"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Wilson WH, Bryant G, Bates S <i>et al.<\/i> EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin\u2019s lymphoma. J Clin Oncol. 1993; 11: 1573-1582.","DOI":"10.1200\/JCO.1993.11.8.1573"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Khaled HM, Zekri ZK, Mokhtar N <i>et al.<\/i> A randomized EPOCH vs. CHOP front-line therapy for aggressive non-Hodgkin\u2019s lymphoma patients: long-term results. Ann Oncol. 1999; 10: 1489-1492.","DOI":"10.1023\/A:1008395014398"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Maurer MJ, Ghesqui\u00e8res H, Jais JP <i>et al.<\/i> Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014; 32: 1066-1073.","DOI":"10.1200\/JCO.2013.51.5866"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/62\/4\/62_22026\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T05:18:13Z","timestamp":1715318293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/62\/4\/62_22026\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.22026","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"22026"}}